Dramatic Clinical Response to a Novel Form of Cell Therapy SL-28 in a Patient with Prostate Cancer and Bone Metastasis: A Case Report
SL-28 was efficient and safe approach in a patient with stage IV prostate cancer, supporting its potential in an allogeneic cell therapy for advanced malignancies.
Authors
- Maria Vecherkovskaya (ORCID: https://orcid.org/0000-0003-3543-9884)
- George Tetz (ORCID: https://orcid.org/0000-0003-3205-9018)
- Victor Tetz (ORCID: https://orcid.org/0000-0001-9047-6763)
- Kristina Kardava
- Olzhas Shulenbayev (ORCID: https://orcid.org/0000-0002-6132-4549)
- Alireza Khodadadi‐Jamayran (ORCID: https://orcid.org/0000-0003-2495-7504)
- Aristotelis Tsirigos
Institutions
- Almaty Management University (KZ)
- University of International Business (KZ)
- Precision for Medicine (United States) (US)
- Tesla Laboratories (United States) (US)
- International Information Technologies University (KZ)
- Io Therapeutics (United States) (US)
- New York University (US)
Publication Details
- Journal
- ImmunoTargets and Therapy
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2147/itt.s547989
- Citations
- 1
- Primary Topic
- Mesenchymal stem cell research
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- School of Medicine, New York University